|
Toshiba's New NEMIO XG Ultrasound Upgrade
Improves Diagnosis and Patient Care Newly Available Clinical Applications Enhance Image Quality, Accuracy and Efficiency TUSTIN, Calif., July 26, 2006 – Toshiba America Medical Systems, Inc. today announced the availability of a new upgrade for the popular Nemio™ ultrasound system. Using next-generation technology, the Nemio XG provides the image quality needed to render a fast, accurate diagnosis – limiting the number of patients who are referred for more serious procedures, testing and follow up. “We are constantly advancing our ultrasound technologies and the next generation Nemio XG provides cutting-edge benefits for both doctors and patients,” said Gordon Parhar, director, Ultrasound Business Unit, Toshiba. “This technology, with its increased clinical applications and improved image quality, will allow many patients to receive a diagnosis in just one doctor visit, rather than receiving an ultrasound and then possibly a second test, like an MRI. The level of diagnostic confidence is increased significantly by the Nemio XG.” The next-generation Nemio XG features enhancements from Toshiba’s flagship Xario ultrasound system, designed to expand diagnostic capabilities and improve clinical insight. Using highly developed clinical applications, the Nemio XG technology provides:
With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. Toshiba Medical Systems Corp., an independent group company of Toshiba Corp., is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, Cath & EP Labs, X-ray, Ultrasound, Nuclear Medicine, MRI and information systems. Toshiba Corp. is a leader in information and communications systems, electronic components, consumer products, and power systems. Toshiba has approximately 161,000 employees worldwide and annual sales of $54 billion. Source: Toshiba America Medical Systems, Inc. |
Angioplasty.Org Home • PatientCenter
this press release is posted as a reader
service by Angioplasty.org,
an editorially independent informational health
site
which has received unrestricted educational grants from
Medtronic plc,
TCROSS NEWS, Toshiba
America
Medical Systems, Volcano
Corporation, Terumo
Medical Corporation
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY
All content, including text, photos and video
©Copyright Venture Digital LLC 1996-2021